Fact Check: Edited BioNTech CEO clip resurfaces with false vaccine claim
The CEO of BioNTech Ugur Sahin was inoculated in early 2021 with the COVID-19 vaccine his team developed with Pfizer, a ...
Promising Oncology Pipeline and Financial Strength Drive BioNTech’s Growth Prospects
Asthika Goonewardene, an analyst from Truist Financial, has initiated a new Buy rating on BioNTech SE (BNTX).Stay Ahead of the Market:Discover ...
BioNTech SE ADR falls Wednesday, underperforms market
The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...
FiercePharma6d
BioNTech inks settlements with NIH, Penn in COVID-19 vaccine royalty disputes
The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...
BioNTech SE ADR rises Tuesday, outperforms market
The BioNTech SE ADR BNTX rose 5.55% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the ...
Hosted on MSN2d
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike
Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid tests.
Penn to receive $467M under settlement with BioNTech over Covid-19 vaccine royalties
Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.
Penn’s royalties from Pfizer-BioNTech COVID-19 vaccine grow to at least $2 billion after new settlement
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
Stocktwits on MSN11d
BioNTech Stock In Focus After $791.5M Settlement With NIH: Retail Cautious
Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...
Yahoo Finance13d
BioNTech's Big Moves: $1.2 Billion Settlements and a Game-Changing Cancer Bet
Big moves are shaking up BioNTech (NASDAQ:BNTX) this week, and investors are taking notice. The German biotech heavyweight ...
BioNTech Target of Unusually High Options Trading (NASDAQ:BNTX)
BioNTech SE (NASDAQ:BNTX – Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 4,599 call options on the company. This represents an increase of ...
Pharmaceutical Technology4d
Trastuzumab pamirtecan by BioNTech for Solid Tumor: Likelihood of Approval
Trastuzumab pamirtecan is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success ...